J. Chan

发表

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

Thomas D. Wu, R. Gentleman, R. Neve, 2012, Genome research.

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor

M. Belvin, K. Hoeflich, J. Chan, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Abstract A250: Preclinical combination efficacy and identification of biomarkers of MEK and PI3K inhibitors in phase I

M. Belvin, K. Hoeflich, H. Koeppen, 2009 .

Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action

G. Schaefer, J. Chan, M. Hafner, 2022, The Journal of biological chemistry.

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Ariana Peck, Shiuh-Ming Luoh, Steve Price, 2013, Nature.

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

Amy Young, M. Belvin, K. Hoeflich, 2013, Proceedings of the National Academy of Sciences.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

M. Belvin, S. Seshagiri, Z. Modrušan, 2009, Cancer research.

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

Saroja Ramanujan, Kapil Gadkar, Daniel C. Kirouac, 2017, npj Systems Biology and Applications.

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

Mark Merchant, M. Belvin, I. Kasman, 2012, Cancer research.

Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.

J. Chan, E. Choo, E. Plise, 2014, Molecular pharmaceutics.

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF V600E Mutational Status and Sustained Extracellular

M. Belvin, S. Seshagiri, Z. Modrušan, 2009 .

Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle

F. Gnad, M. Belvin, G. Hatzivassiliou, 2017, The Journal of Biological Chemistry.

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

K. Gadkar, D. Kirouac, S. Ramanujan, 2017, npj Systems Biology and Applications.

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Lily Shao, Mark Merchant, Eva Lin, 2017, PloS one.

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

M. Belvin, D. Kirouac, H. Koeppen, 2018, PloS one.

Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.

P. Savy, Steve Price, M. Belvin, 2012, Journal of medicinal chemistry.

132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo

M. Belvin, K. Hoeflich, H. Koeppen, 2010 .

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .

Clinical responses to ERK inhibitor (GDC-0994) treatment combinations predicted using a Quantitative Systems Pharmacology model of MAPK signaling in BRAF(V600E)-mutant colorectal cancer

K. Gadkar, D. Kirouac, S. Ramanujan, 2016 .

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

M. Belvin, K. Hoeflich, L. Friedman, 2013, Proceedings of the National Academy of Sciences.